Zhongke CELFULL

CELFULL (also known as Zhongke CELFULL) is a clinical-stage biotechnology company dedicated to anti-aging and longevity research. Founded by a team of PhDs with academic roots at Cornell University, the company integrates artificial intelligence with aging biology to develop high-bioavailability nutraceuticals and therapeutic candidates. Its proprietary TURN A Drug Delivery Platform utilizes nano-microsphere technology to optimize the absorption of NAD+ precursors, such as NMN and NADH. CELFULL's pipeline includes therapeutic programs for Phenylketonuria (PHE1411) and age-related sleep disorders (CF2108), alongside a broad range of commercialized longevity supplements. The company operates globally with headquarters in the United States and research facilities in Shenzhen, China, maintaining collaborations with leading institutions like Harvard Medical School.